SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001493152-24-049661
Filing Date
2024-12-11
Accepted
2024-12-11 17:21:40
Documents
6

Document Format Files

Seq Description Document Type Size
1 form424b5.htm 424B5 534408
2 form424b5_001.jpg GRAPHIC 7458
3 form424b5_002.jpg GRAPHIC 31506
4 form424b5_003.jpg GRAPHIC 35388
5 form424b5_004.jpg GRAPHIC 39619
6 form424b5_005.jpg GRAPHIC 4961
  Complete submission text file 0001493152-24-049661.txt   699924
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 424B5 | Act: 33 | File No.: 333-276650 | Film No.: 241542453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)